Meitav Investment House Ltd. increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 29.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,066,322 shares of the company's stock after purchasing an additional 473,293 shares during the quarter. Meitav Investment House Ltd. owned approximately 1.00% of Cellebrite DI worth $34,797,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Pathway Financial Advisers LLC grew its stake in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. Tower View Wealth Management LLC grew its stake in Cellebrite DI by 1.2% in the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company's stock valued at $2,200,000 after buying an additional 1,500 shares during the last quarter. Juncture Wealth Strategies LLC increased its stake in shares of Cellebrite DI by 42.2% in the third quarter. Juncture Wealth Strategies LLC now owns 59,498 shares of the company's stock worth $1,002,000 after purchasing an additional 17,652 shares during the period. Strategic Advisors LLC acquired a new position in shares of Cellebrite DI during the third quarter worth approximately $474,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after acquiring an additional 1,017 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.
Cellebrite DI Trading Down 1.1 %
Shares of NASDAQ:CLBT traded down $0.21 during mid-day trading on Thursday, reaching $18.15. The stock had a trading volume of 558,946 shares, compared to its average volume of 1,121,514. The firm has a market cap of $3.74 billion, a PE ratio of -34.64, a price-to-earnings-growth ratio of 2.52 and a beta of 1.52. The firm has a 50 day simple moving average of $17.38 and a two-hundred day simple moving average of $13.91. Cellebrite DI Ltd. has a twelve month low of $6.55 and a twelve month high of $18.75.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. Cellebrite DI's revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the company posted $0.05 EPS. On average, equities analysts anticipate that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently weighed in on CLBT. Needham & Company LLC lifted their target price on Cellebrite DI from $14.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Lake Street Capital upped their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Craig Hallum increased their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Bank of America increased their price objective on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $14.00 to $15.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $18.57.
Read Our Latest Stock Analysis on CLBT
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
